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Abstract
Background: Recent cohort studies of randomised controlled trials have provided evidence of within-study
selective reporting bias; where statistically significant outcomes are more likely to be more completely reported
compared to non-significant outcomes. Bias resulting from selective reporting can impact on meta-analyses,
influencing the conclusions of systematic reviews, and in turn, evidence based clinical practice guidelines.
In 2006 we received funding to investigate if there was evidence of within-study selective reporting in a cohort of
RCTs submitted to New Zealand Regional Ethics Committees in 1998/99. This research involved accessing ethics
applications, their amendments and annual reports, and comparing these with corresponding publications. We did
not plan to obtain informed consent from trialists to view their ethics applications for practical and scientific
reasons.
In November 2006 we sought ethical approval to undertake the research from our institutional ethics committee.
The Committee declined our application on the grounds that we were not obtaining informed consent from the
trialists to view their ethics application. This initiated a seventeen month process to obtain ethical approval. This
publication outlines what we planned to do, the issues we encountered, discusses the legal and ethical issues, and
presents some potential solutions.
Discussion and conclusion: Methodological research such as this has the potential for public benefit and there is
little or no harm for the participants (trialists) in undertaking it. Further, in New Zealand, there is freedom of
information legislation, which in this circumstance, unambiguously provided rights of access and use of the
information in the ethics applications. The decision of our institutional ethics committee defeated this right and
did not recognise the nature of this observational research.
Methodological research, such as this, can be used to develop processes to improve quality in research reporting.
Recognition of the potential benefit of this research in the broader research community, and those who sit on
ethics committees, is perhaps needed. In addition, changes to the ethical review process which involve separation
between those who review proposals to undertake methodological research using ethics applications, and those
with responsibility for reviewing ethics applications for trials, should be considered. Finally, we contend that the
research community could benefit from quality improvement approaches used in allied sectors.
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A well conducted randomised controlled trial (RCT) is
the most reliable method for measuring the effectiveness
of a clinical intervention. When properly implemented,
many of the biases observed in non randomised and
observational studies can be removed [1]. However, the
benefits of the RCT study design are only realised when
they are properly implemented and reported.
T h e r ei sal a r g eb o d yo fl i t e r ature, across many disci-
plines, suggesting that current conduct and reporting of
many RCTs is inadequate (examples include [2-6]).
Inadequate conduct and reporting of RCTs has been
associated with bias in estimating intervention effects
[7-10]. For one component, inadequate allocation con-
cealment, this bias has been estimated as a 30% exag-
geration in intervention effect [7]. Other forms of bias
can occur from selective reporting of results. This can
occur when there is selective reporting of either the
entire RCT (between-study selective reporting bias or
publication bias), or of the results within a RCT (within-
study selective reporting bias).
Much research has been undertaken investigating
between-study selective reporting bias, but relatively lit-
tle investigating within-study selective reporting bias.
However, some recent studies investigating the latter
have highlighted some concerning results [11-17]. Two
landmark studies investigated the prevalence of unre-
ported outcomes by comparing study trial protocols
with subsequent trial publications. They estimated that
for efficacy outcomes, 71% (95% confidence interval
( C I ) :6 1 % ,7 9 % )a n d8 8 %( 9 5 % C I :7 5 % ,9 5 % )o fR C T s
had at least one unreported outcome [12,13]. These stu-
dies estimated that statistically significant outcomes had
a higher odds of being fully reported compared with
non-significant outcomes for both efficacy and harm
outcomes; where fully reported was defined as outcomes
with sufficient data for inclusion in a meta-analysis. For
efficacy outcomes the odds ratios ranged from 2.4 (95%
CI: 1.4, 4.0) to 2.7 (95%CI: 1.5, 5.0) while for harm out-
comes the range was from 4.7 (95%CI: 1.8, 12.0) to 7.7
(95%CI: 0.5, 111). A systematic review summarising the
evidence from empirical studies investigating publication
bias and within-study selective reporting bias concluded
for the latter that statistically significant outcomes were
more likely to be more completely reported compared
to non-significant outcomes [18]. Four studies, including
those above, contributed to this conclusion.
In addition to misrepresenting the results from the
RCT, bias arising from selective reporting can impact on
meta-analyses [14], influencing the conclusions of sys-
tematic reviews, and in turn, evidence based clinical
practice guidelines [19-21]. This will, in some instances,
result in wrong answers to important clinical questions.
Patients, clinicians, and health policy makers rely on this
information for evidence based decision making.
Researchers and grant funding bodies rely on this infor-
mation to inform future research including the need for
future RCTs [21,22].
There has been no published research in New Zealand
(NZ) investigating within-study selective reporting bias.
Awareness of the quality of reporting of RCTs is a first
step in determining if there is a need to develop pro-
cesses to ensure adequate reporting of future RCTs. In
this publication we report on a methodological research
project we planned to undertake to investigate the qual-
ity of reporting of RCTs in NZ, including within-study
selective reporting bias. We discuss the ethical chal-
lenges we faced in trying to undertake this research and
discuss potential solutions.
What did we plan to do?
T w oo ft h ea u t h o r so ft h i sp u b l i c a t i o n( J E M ,G P H )
attempted to undertake a study similar to Chan et al’s
[12] study to investigate within-study selective reporting
bias of outcomes in a cohort of RCTs submitted to New
Zealand Regional Ethics Committees (NZRECs) in 1998/
99, where the trial was based in NZ. Additional aims of
the study included: (i) describing the process and out-
come of the cohort of RCTs, (ii) assessing the adequacy
of reporting of RCTs and identifying barriers to ade-
quate reporting, and (iii) comparing the consistency of
ethics applications with corresponding published articles
in terms of: primary outcome(s), secondary outcome(s),
sample size, methods of allocation concealment used,
and blinding. We were successful in receiving an inter-
nal university grant (University of Otago Research
Grant), through a competitive grant process, in October
2006, which provided one years funding.
In brief, the study involved identifying and accessing
ethics applications of approved RCTs submitted to
NZRECs in 1998/99, along with their amendments and
annual reports. In NZ there is no requirement to submit
a full trial protocol as part of the ethics application and
so the information contained in the ethics applications
is limited and variable. However, despite this, they still
provide the best source of information to evaluate the
completeness of RCT reporting in NZ. We chose the
years 1998/99 to provide a reasonable length of time for
the RCTs to be carried out, written up, and published
[23]. A literature search of relevant databases would
then be carried out to identify publications of the
included RCTs. Data would be extracted from the ethics
applications, annual reports, amendments, and publica-
tions. Two questionnaires would be sent to trialists. In
the first questionnaire, trialists would be provided with a
list of unreported outcomes which had been identified
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article. The statistical significance of unreported out-
comes and reasons for omitting them would be solicited.
A second questionnaire would assess trialists’ knowledge
of the CONsolidated Standards Of Reporting Trials
(CONSORT) statement, a guideline for reporting RCTs,
and barriers to its use [24].
To identify ethics applications for inclusion, we planned
to screen full ethics applications submitted to NZRECs in
1998/99. This was necessary since it is often not possible
to identify which applications are RCTs from information
contained in the NZRECs’ annual reports.
We planned to actively seek the participation of trial-
ists to complete the questionnaires. However, for practi-
cal and scientific reasons, we did not plan to obtain
consent from trialists to access their ethics application.
Practically, if we were only able to use NZREC annual
reports to identify ethics applications, we would be lim-
ited to the title of the ethics application and the name
of the primary investigator. Finding contact details of all
the potential investigators would be difficult given the
age of the records. Over these two years, we estimated
that in excess of 1500 applications were submitted to
NZRECs for consideration. In addition, we were con-
cerned that the proportion of investigators who would
provide consent for us to access their ethics applications
would be low [25]; providing little yield for a large
effort. Moreover, it could prejudice the scientific value
of the study since trialists with less exacting reporting
practices might be less likely to allow us access to their
ethics applications, thus biasing and undermining the
results of the study.
Moreover, we believed that there was minimal risk to
trialists by us undertaking this study. Two issues which
we considered trialists may have concerns about were
identification of defects in their study reporting which
could be used to disadvantage them, and disclosure of
commercial and intellectual secrets from their ethics
application. In regard to both issues, only the two
researchers on the grant (JEM, GPH) and their research
assistant would view the ethics application. Information
from the ethics applications would be treated confiden-
tially, and importantly, in publications arising from our
research we would present the results using summary
statistics on groups of ethics applications/publications.
Therefore, studies would be highly unlikely to be identi-
fiable, thus protecting the anonymity of the trialists.
Finally, ethics applications are official information held
by the NZ public sector and therefore access to them is
governed through the Official Information Act 1982.
Under this act, information must be made available
when requested unless good reason exists for it to be
withheld. It is the ethics committee’s responsibility to
make applicants aware of this [26].
What issues did we encounter?
The timeline for the project is outlined in Figure 1. In
November 2006 we sought ethical approval for the pro-
ject from our institutional ethics committee, the Univer-
sity of Otago Human Ethics Committee. This ethics
committee is accredited by the Health Research Council
Ethics Committee and is one of a number of commit-
tees in NZ which forms part of a national system of
ethics review (Figure 2) [27]. Our institutional ethics
committee has two categories of application; category A
applications are considered by the Committee, while
category B applications are for low-risk research invol-
ving human participants, and are assessed at the
Figure 1 Project history of “Conduct and reporting of randomised controlled trials in New Zealand”.
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criteria for category A, we made a decision to submit it
as such, so that it would be considered by the full Com-
mittee, because we felt there were sensitivities involved
in accessing ethics applications without gaining
informed consent from trialists to do so.
The ethics application was declined by our institu-
tional ethics committee in November 2006, and this
initiated three months of communication with the Com-
mittee (Figure 1). The primary issue raised by the Com-
mittee was informed consent.
“The application states that the “participants” for the
study are “investigators who submit applications for
approval for randomised controlled trials that are
published at the time of the search”. A fundamental
principle of ethical research is, of course, informed
consent. The Committee is concerned that “partici-
pants” are not informed prior to the research. They
will not be exercising voluntary choice to participate
nor will they be informed of the purpose, methods,
risks, inconvenience and possible outcomes, includ-
ing publication of the research. Also, investigators
who have submitted applications to relevant ethics
Committees have not agreed to participate in such a
project as part of their application process.”
(Personal communication: manager, Academic Com-
mittees, University of Otago, 21 November 2006)
The Committee also questioned “... the relevance of the
research given the advent of clinical trial registers and is
of the view that such oversight as that proposed in the
application may be obsolete.” (Personal communication:
manager, Academic Committees, University of Otago, 21
November 2006). They perceived, and did not approve of
us “becoming self-appointed auditors”,a n df e l tt h a ta
project such as this would “... more appropriately be
undertaken as an audit by the relevant ethics commit-
tees” (Personal communication: manager, Academic
Committees, University of Otago, 21 November 2006).
They requested clarificatio no ft h ed a t at ob ee x t r a c t e d
from the ethics application (Personal communication:
manager, Academic Committees, University of Otago,
19 January 2007). They questioned “... whether applica-
tions for ethical approval that have been submitted to an
ethics committee are in the public domain” and ques-
tioned “Will authors be surprised to be contacted about
information that they have provided in their ethics appli-
cations?” (Personal communication: manager, Academic
Committees, University of Otago, 19 January 2007).
In consultation with researchers with expertise in ethi-
cal and legal issues (CP, PR), we responded to our
Figure 2 New Zealand National System of Ethics Review.
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reasons for why we considered it was reasonable to
undertake this research without obtaining informed con-
sent. In brief, we provided legal justification for acces-
sing the ethics applications with reference to the two
NZ statutes that deal with freedom of information, the
Official Information Act 1982 and the Privacy Act 1993.
The former provided every reason why the information
sought ought to be disclosed, and the latter provided no
justification for it to be withheld or not used. The legal
presumption was that the information concerned ought
to be made available. There was no legal impediment
standing in the way. Indeed, the public policy reasons
underlying the enactment of freedom of information
legislation would have been satisfied had the informa-
tion been made available for the purpose of holding
both trialists and ethics committees publicly accounta-
ble. Details of the legal issues are available in Additional
file 1 - What are the legal issues?
We provided ethical justification for undertaking the
p r o j e c tw i t h o u to b t a i n i n gi n f o r m e dc o n s e n tf r o mt h e
trialists to access their ethics applications, making refer-
ence to the Ethical Guidelines for Observational Studies
[28]. This document, prepared by the National Ethics
Advisory Committee (NEAC), aims to provide guidance
to researchers and ethics committees for carrying out
observational research. It proposes that access to perso-
nal health information without consent is justifiable
when seeking consent would not be practicable or
would affect the scientific value of the study; and when
there would be no disadvantage to the participants; and
there is a public interest in the study.
We provided clarification of the data to be extracted
from the ethics applications, justification for undertaking
the research with the advent of clinical trial registers,
and reasons for why we considered we were an appro-
priate group to do this. While registration of clinical
trials is a positive step to improve reporting, we
believed, and conveyed to our institutional ethics com-
mittee, that this alone was unlikely to be the only solu-
tion since ethics committees in NZ do not insist on
registration as a requirement for ethical approval, only a
few journals insist on pre-registration as a condition of
publication, and currently there is no requirement to
register all outcomes in a trial. We responded to the lat-
ter criticism by stating that ethics committees in NZ
generally have neither the resources nor the expertise to
undertake such studies and that researchers have carried
out such studies previously. Further, the authors of this
study (JEM, GPH) have methodological and statistical
expertise consistent with researchers who have carried
out previous studies. In addition to appropriate exper-
tise, we stated that independence from the ethics com-
mittee process should be considered a strength. We
responded to the question of “surprise” by stating that
trialists may be surprised when contacted, but they
would be provided with an explanation about the pro-
ject and the rationale for accessing their ethics applica-
tion, and would have the option of not completing the
questionnaire. Finally, we provided our institutional
ethics committee with a letter of support which we had
received from the NEAC after advising them of our
study (Figure 2). NEAC considered that this study
would add valuable NZ dimensions to the reporting of
RCT results.
After three months of communication, and considera-
tion of all the information supplied, our institutional
ethics committee declined the application. The Commit-
tee did not accept that the principal investigators
needed to be contacted (i.e. to complete the question-
naires) and believed that “the research would continue
to be valid if this part was modified” (Personal commu-
nication: manager, Academic Committees, University of
Otago, 27 February 2007). They stated that if we wished
to undertake the study without making contact with the
principal investigators, we should submit an amended
application for ethical consideration. Our institutional
ethics committee also regarded the use of the Official
Information and Privacy Acts as “... unduly aggressive”
(Personal communication: manager, Academic Commit-
tees, University of Otago, 27 February 2007).
A second ethics application was submitted in April
2007 (Figure 1). We presented three options which we
believed addressed the concerns raised by our institu-
tional ethics committee in various ways (Figure 3). We
considered option A (which was similar to our original
ethics application) to be the most ethical and scientifi-
cally tenable. It provided the most transparency since
trialists were informed of the study and that we had a
copy of their ethics application. Scientifically, it was
more likely to provide complete data on outcomes not
reported in publications and provide trialists with an
opportunity to explain discrepancies between their
ethics application and publication(s), which may be
legitimate [29].
The second application was also declined on grounds
of informed consent not being obtained from trialists
before retrieving their ethics applications.
“The Human Ethics committee has construed that
the “primary authors” of publications to be the parti-
cipants in this project. A guiding ethical principle of
the Committee is for researchers to respect the wel-
fare, rights, beliefs and perceptions of participants.
In view of the Human Ethics Committee it is the
researcher’s responsibility to minimise risks of harm
or discomfort in the participants and most impor-
tantly research protocols should be designed to
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ticipants. A fundamental principle of ethical clear-
ance is that participation is voluntary and that
informed consent must be provided before indivi-
duals participate in the project.” (Manager, Aca-
demic Committees, University of Otago, 27 April
2007)
However, the ruling was somewhat ambiguous. The
Committee stated that while we were legally able to
undertake the ‘audit’ component of the project without
the need for ethical clearance, they could not approve
the process. They had particular concerns surrounding
us contacting trialists, and concluded with the following:
“In particular, the second stage, involving a response to
questionnaires, cannot proceed without ethical approval.
It is possible, however, for you to conduct this first
‘audit’ stage without the Committee’s approval, and to
submit an application to complete the second stage
once you have identified the potential participants.”
(Personal communication: manager, Academic Commit-
tees, University of Otago, 27 April 2007).
In parallel with the process of seeking ethics approval
from our institutional ethics committee, in March 2007,
we contacted the National Co-ordinator of Ethics Com-
mittees, Ministry of Health( M o H ) ,t od e t e r m i n et h e
practicalities of retrieving the ethics applications from
the MoH archives. Following several months of corre-
spondence, we were asked to submit an application for
expedited review by the Multi-Region Health and Dis-
ability Ethics Committee (MRHDEC). The MRHDEC
reviews health and disability research proposals which
a r eu n d e r t a k e ni nm o r et h a no n er e g i o n( F i g u r e2 ) .
Expedited review is used to assess low-risk observational
research or audit and related activity. These applications
are reviewed by only the chairperson, or a delegated
member of the Committee.
We submitted our application in November 2007. The
chair of the MRHDEC considered the application and
determined that since we were contacting trialists, the
project needed to be considered by the full committee
(December 2007). An application for review by the full
Committee was submitted in January 2008. This was
considered at the February meeting, where it received
ethical approval, subject to providing two additional
forms (locality assessment, evidence of consultation with
an appropriate Maori group). Unconditional ethical
approval was provided in March 2008.
We wrote to our institutional ethics committee in
March 2008 advising them that we had received ethical
approval to undertake the study from the MRHDEC,
that we planned to proceed with the study, and asked
them to raise any concerns with us. The Committee
responded in May 2008 advising us that “The Commit-
t e ew o u l dl i k et oe m p h a s i s et h a tt h e yt a k en oe t h i c a l
responsibility for this study or the outcomes, consider-
ing their continued disapproval regarding the lack of
informed consent.”,f o l l o w e db y“The Committee
acknowledges that the approval from the Regional Com-
mittee gives the researchers the authority to proceed,
but that this approval does not equate to approval from
University of Otago Human Ethics Committee.”
Figure 3 Three proposed options to undertake the study.
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tees, University of Otago, 5 May 2008).
At this stage our head of department, who had been
copied into much of the correspondence, wrote to our
institutional ethics committee stating that he had read
the ethics application and the NEAC guidelines for
observational research [28] and was satisfied that the
project was ethical and was happy for it to be based in
the Department (Personal communication: Head of
Department, Department of Preventive and Social Medi-
cine, University of Otago, 14 May 2008). The Committee
responded that they reaffirmed their position after
examining the guidelines (Personal communication:
manager, Academic Committees, University of Otago, 10
July 2008).
Discussion
Participants of RCTs volunteer for many reasons. These
include a belief that their participation may result in
some improvement to their health, financial incentives,
or altruistic reasons; such as the research they participate
in resulting in benefits for others with the same condition
i nt h ef u t u r e[ 2 1 , 3 0 , 3 1 ] .T h e yd on o tp a r t i c i p a t et o
improve the financial status of pharmaceutical compa-
nies, nor do they participate to advance the career of aca-
demic researchers. In volunteering, they give their time
and may experience inconvenience and financial loss.
Moreover, there are potential harms associated with their
participation. Trialists have a moral responsibility to the
participants of their RCTs to conduct and report the
results to the highest possible standard [21,32].
In recognition of substandard reporting practices,
there have been many initiatives employed in an attempt
to bring about improved reporting. These have included
the development of reporting guidelines [24], voluntary
registration of clinical trials, pre-registration of clinical
trials as a condition of publication [33], the World
Health Organization International Clinical Trials Regis-
try Platform [34], journals accepting trial protocols for
publication, the recently updated World Medical Asso-
ciation Declaration of Helsinki (principle 19) [35], and
in the United States, legislation to make findings of clin-
ical trials publicly available within a specific timeframe
[36]. Some of these initiatives have contributed to an
improvement in reporting practices [37] and this is
likely to continue as greater requirements are placed on
trialists to provide explicit information regarding out-
comes and analytical methods prior to commencement
of the trial. However, empirical research has still identi-
fied evidence of within-study selective reporting in
cohorts of RCTs [15-17], some of which are relatively
recent [15,17].
While internationally there is evidence of within-study
selective reporting, we are unaware of any studies
investigating this in NZ. An important step to improv-
ing the quality of reporting of RCTs is to assess current
reporting against agreed standards of best practice so
that processes can be developed to ensure adequate
reporting if they are required. This approach is analo-
gous to that used to improve quality in other sectors,
including healthcare delivery and education. In these
sectors performance measurement is used to determine
areas for improvement, identify strategies with the
potential to improve quality, and evaluate the impact of
these strategies. As new evidence emerges to guide best
practice, performance standards change, hence quality
improvement is a continuous process.
In this publication we have considered the potential
benefits and harms associated with undertaking the pro-
posed research and have provided reasons why we
believe the benefits out-weigh the harms. Other ethics
committees, internationally, have come to the same con-
clusion and provided ethical approval for similar metho-
dological research where retrospective access to ethics
applications without informed consent from trialists has
been sought [32]. However, our institutional ethics com-
mittee is not alone in its decision to not provide ethical
approval for such research, with committees in Austra-
lia, the United Kingdom, and South Africa denying per-
mission [32]. While some variation in ethics
committees’ decisions is expected due to the intrinsic
nature of the committees, for methodological studies
such as this, where there is public interest and little or
no harm, the variation in decisions is intriguing and
concerning. Reasons for this variation may include con-
cerns about legal contractual obligations, litigation, and
fear of upsetting multinational sponsers who may take
their trials elsewhere. Variation may also exist from
approaches the ethics committees use when considering
ethical principles, and the level of importance they place
on this type of methodological research. These two rea-
sons are discussed further.
The reasons given for our institutional ethics commit-
tee’s decision were largely based on the view that
informed consent was a fundamental principle which
permitted no exception. In taking this view the Commit-
tee was treating ethical principles as if they were legal
rules. Yet principles are in conflict here, as is commonly
the case in deliberation about the ethics of specific
research projects. As well as autonomy, principles of
beneficence, non-maleficence, and integrity are also rele-
vant. This research had potential public benefit, not
doing it may perpetuate a harm, and the whole under-
taking supports the integrity of the research enterprise.
In law there are normally ‘rules of recognition’ that
tell which rule prevails when they come into conflict. In
ethics there are no agreed rules of recognition. Further-
more, deliberation simply at the level of rules or
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detail of specific projects. Practical judgement is what is
used in daily ethical decision-making and requires
detailed knowledge of the facts of the case. Judgement
also matters for research ethics. In a piece comparing
the claims of ethical theory with practical judgement,
Jonsen notes that “Justification of any particular moral
claim comes rarely from a single principle ... but usually
from a convergence of many considerations, each partly
persuasive but together convincing with plausible prob-
ability” [38]. A central consideration for informed con-
sent is what is being consented to. There is a huge
difference between a clinical trial where participants
may be asked to give their consent to receive a relatively
untested intervention and consent to allow a document
which contains no personal information to be examined.
In 2000, one of us (CP) reported on health research-
ers’ views of ethics committee functioning and con-
cluded that the quality of advice needed to be
addressed: “The temptation to develop rigid rules to fit
all circumstances can divert ethics committees from
their chief function in which principles can be tested
against the special circumstances of each case” [39].
Subsequently local guidelines designed to encourage
deliberation of this sort for observational research,
audits, and related activities, have been published [28].
However, our experience indicates that, at least for this
ethics application, a rules-based approach is still evident.
T h ei m p o r t a n c eo ft h i st y p eo fm e t h o d o l o g i c a l
research may not be valued or understood by members
of ethics committees. In an editorial discussing a publi-
cation which investigated the effect of study design in
RCTs on the magnitude of intervention effect, Hughes
commented that “i ti se a s ya n dm a yb et e m p t i n gt o
overlook reports addressing methodologic issues in clini-
c a lt r i a l sa n dd i s m i s st h e mt ot h en i c h em a r k e to fp r o -
fessional statisticians and clinical academic researchers.”
[40]. Indeed, our institutional ethics committee was not
convinced that the research was necessary. This was
despite the fact that the research had been assessed by a
panel of researchers for the purpose of determining
whether it should receive a competitive internal univer-
sity grant; which the panel deemed it should. Ethics
committees must deal with scientific aspects that
impinge on matters of potential harms and benefits. But
it is questionable whether they should adjudicate on the
worth of the research when scientific peers have
approved it for funding. If committees are to undertake
such a task, it would seem essential that the composi-
tion of the committee includes appropriate expertise to
credibly assess the submitted applications [41].
The time between submitting the first ethics applica-
tion and receiving ethical approval took seventeen
months. The research project was funded for one year
and with continued delays in receiving ethical approval,
we ultimately were unable to use the funding to under-
take the component of the project comparing ethics
applications with their corresponding publication. Our
experience is not unique, and if experiences such as this
are not to be repeated in the future, mechanisms need
to be developed to permit this type of research to be
undertaken. While education of researchers about the
importance of methodological research is one potential
solution, more practical measures may be more effective.
For example, prospectively informing trialists that their
ethics application may be used in future methodological
research or audits.
Alternatively, consideration could be given to chan-
ging the ethical review process to avoid conflict in deci-
sion making. It might help to have a separation between
those who review proposals to undertake methodologi-
cal research using ethics applications, and those with
responsibility for reviewing ethics applications for RCTs.
When there is no separation of these roles, this creates
a potential conflict of interest. The ethics committee
may regard the methods as ethical but be reluctant to
approve it because of their relationship to the trialists
and a possible, unwarranted, concern that identified fail-
ures of good reporting practice may implicate ethics
committees themselves. In our case, although our insti-
tutional ethics committee did not have this dual role, it
did suggest that such research would “more appropri-
ately be undertaken as an audit by the relevant ethics
committee”, suggesting that it had somewhat of a con-
flict of interest; perhaps stemming from a concern of
being included in future methodological research.
To address this sort of concern Chan et al [32] sug-
gested a body, independent of the ethics committees,
could be created which would consist of members who
have expertise in ethics, public health, and the laws of
privacy, contract, and intellectual property. This body
would assess methodological research protocols and, if
they were satisfied that the researcher’s intention was to
serve a greater public good while also undertaking to
protect the privacy and proprietary rights of the appli-
cants, could grant access to the ethics applications.
Regardless of the approach adopted for the ethical
review of methodological research such as this, we con-
cur with Chan et al that trial ethics applications should
be treated confidentially and only aggregated data
should be reported in resulting publications [32]. In our
first application, and subsequent correspondence, we
stated that our best efforts would be made not to allow
identification of any particular study, and hence its
investigators, but because of the relatively small number
of studies, it could not be guaranteed that studies would
not be identified by a small number people (e.g. other
researchers working in the same area). We were,
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we stated that there was potential for embarrassment of
trialists if it was pointed out that they may not have
acted with complete scientific and ethical integrity and
that this may not be a “bad thing”.
We contend that a culture of continuous quality
improvement is overdue in research and that the
research community could benefit from a more explicit
approach to quality improvement used in allied sectors.
Improving quality in the conduct and reporting of RCTs
is an ongoing process, driven in part by the findings of
empirical methodological research and, in part, by the
development of new reporting standards to address
identified problems. Intuitively, improving quality should
be a good fit with the research community since
researchers are used to, and expect critical review of
their research; this is an integral part of the academic
process. A 2007 survey of researchers at a non-govern-
ment research institute affiliated with a major children’s
hospital in Australia, exemplifies this with 79% (95%CI:
70%, 86%) reporting that they felt that auditing was an
important part of the research process (response rate of
79%) [42]. Consistent with continuous quality improve-
ment approaches in other sectors, the aim is to identify
and address systemic causes of quality problems rather
than apportioning blame to individuals.
Finally, there is a groundswell of researchers advocating
for increased transparency of decision making processes
by ethics committees and refuting concerns about the
threat such transparency poses to researcher confidenti-
ality and academic interests [43,44]. Greater transparency
of decisions may confer many benefits. It may lead to
greater protection of those who participate in clinical
trials, improve the quality of the research, promote
improved trust of ethics committees’ decisions from the
perspectives of researchers and the public, and provide
researchers with opportunities to learn about the ethical
review process. Importantly, a more open process of ethi-
cal review encourages the questioning of decisions and is
consistent with the principles of quality improvement.
Conclusion
Internationally, funders spend billions of dollars on RCTs
annually. However, this investment is only a small frac-
tion of what is spent on providing clinical treatments.
High quality research is required to provide accurate
information on which to base healthcare decisions. Fun-
ders and the public expect that research will be of the
highest quality. To achieve this goal, research using ethics
applications is essential. In NZ we have legislation which
enables this, but we also require the support of the
research community and those who sit on ethics commit-
tees. There are mounting calls for public access to ethics
applications, full protocols and regulatory submissions
[22,32,45]. We join these calls and hope that this publica-
tion promotes discussion of these issues.
Additional file 1: What are the legal issues?. An in-depth discussion of
the legal issues surrounding access to ethics applications in NZ.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1745-6215-11-
28-S1.PDF]
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